The diagnosis of renovascular hypertension with technetium-99m- ethylenedicysteine captopril scintigraphy

Investigative Radiology

Volumn 31, Issue 8, 1996, Pages 497-501

  Ǔgur, Ömer ^a   Caner, Biray ^a   Çekirge, Saruhan ^a   Balkanci, Ferhun ^a   Ergün, Eser Lay ^a   Kostakoǧlu, Lale ^a   Bekdik, Coskun ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

captopril renal scintigraphy; renal artery stenosis; renal imaging; Renovascular hypertension; technetium 99m ethylene dicysteine

Indexed keywords

CAPTOPRIL; FUROSEMIDE; N,N' ETHYLENEDICYSTEINE TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY ANGIOGRAPHY; KIDNEY ARTERY STENOSIS; KIDNEY FUNCTION; KIDNEY PERFUSION; KIDNEY PLASMA FLOW; KIDNEY SCINTISCANNING; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION;

EID: 0029757448     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-199608000-00005     Document Type: Article

References (17)

1. Majd M, Potter BM, Guzzetta PC, Ruley EJ. Effect of captopril on efficacy of renal scintigraphy in detection of renal artery stenosis. J Nucl Med 1983;24:P23. Abstract.
2. Prigent A. The diagnosis of renovascular hypertension: The role of captopril renal scintigraphy and related issues. Eur J Nucl Med 1993;20:625-644.
3. Sfakianakis GN, Bourgoigne JJ, Jaffe D, Kryiakides G, Perez-Stable E, Duncan RC. Single dose-captopril scintigraphy in the diagnosis of renovascular hypertension. J Nucl Med 1987;28: 1383-1392.
4. Verbruggen AM, Nosco DL, Nerom VCG, Bormans GM, Adriaens PJ, De Roo MJ. Technetium-99m-L,L-ethylenedicysteine: A renal imaging agent. 1. Labeling and evaluation in animals. J Nucl Med 1992;33:551-557.
5. Uǧur Ö, Caner B, Çekirge S, et al. Technetium-99m-ethylenedicysteine in the diagnosis and follow-up of renovascular hypertension. Invest Radiol 1996;31:378-381.
6. Schlegel JU, Hamway SA. Individual renal plasma flow determination in 2 minutes. J Urol 1976;116:282-285.
7. Özdemir O, Erbas B, Uǧur Ü, et al. Scintigraphic evaluation of the short and long term renal effects of oral felodipine using technetium-99m-mercaptoacetyltriglycine. Am J Nephrol 1993;13: 249-254.
8. Kabasakal L, Atay S, Vural VA, et al. Evaluation of technetium-99m-ethylenedicysteine in renal disorders and determination of extraction ratio. J Nucl Med 1995;36:1398-1403.
9. Hilson AJW, Maisey MN, Brown CB, Og CS, Bewick MS. Dynamic renal transplant imaging with Tc-99m-DTPA (Sn) supplemented by a transplant perfusion index in the management of renal transplants. J Nucl Med 1978;19:994-1000.
10. Sfakianakis GN, Vonorta K, Zilleruelo G, Jaffe D, Georgiou M. Scintigraphy in acquired renal disorders. In: Freeman LM, ed. Nuclear medicine annual. New York, NY: Raven Press; 1992: 157-224.
11. Nally JV, Chen C, Fine EJ, et al. Diagnosis criteria of renovascular hypertension with captopril renography: A consensus statement. Am J Hypertens 1991;4:S749-S752.
12. Bubeck B, Brandau W, Weber E. Pharmacokinetics of technetium-99m-MAG3 in humans. J Nucl Med 1990;31:1285-1293.
13. Kabasakal L, Turoǧlu HT, Önsel Ç, et al. Clinical comparison of technetium-99m-EC, technetium-99m-MAG3, and iodine-131-OIH in renal disorders. J Nucl Med 1995;36:224-228.
14. Van Nerom CG, Bormans GM, De Roo MJ, Verbruggen AM. First experience in healthy volunteers with technetium-99m L,L- ethylenedicysteine, a new renal imaging agent. Eur J Nucl Med 1993;20:738-746.
15. Nally JV, Black HR. State of the art: Captopril renography. Pathophysiological considerations and clinical observations. Semin Nucl Med 1992;22:85-97.
16. Britton KE, Maisey MN, Hilson AJW. Renal radionuclide studies. In: Maisey MN, Britton KE, Gilday DL, eds. Clinical nuclear medicine. Philadelphia, PA: JB Lippincott Co., 1991.
17. Lee HB, Blaufox MD. Renal functional changes after angiotensin converting enzyme inhibition of nitroprusside in hypertensive rats. J Hypertens 1986;4:S266-S268.